Dr Timothy Yap speaks to ecancer as part of the AACR 2022 meeting about a study evaluating the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumours with DNA damage response defects.

He reports that clinical benefit with disease control for at least 16 weeks was achieved in at least 35% of patients treated with elimusertib and that durable responses were seen over a variety of cancer types.

Dr Yap also explains that the adverse events seen during treatment were reversible and manageable with dose interruption, reduction and supportive measures.